Serum ADMA concentration an independent factor determining FMD impairment in cardiac syndrome X

Upsala Journal of Medical Sciences

Volumn 114, Issue 4, 2009, Pages 221-227

  Haberka, MacIej ^a   Mizia Stec, Katarzyna ^a   Gsior, Zbigniew ^a   Mizia, Magdalena ^a   Janowska, Joanna ^a   Holecki, Michał ^a   Zahorska Markiewicz, Barbara ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Asymmetric dimethylarginine; Cardiac syndrome X; Flow mediated dilatation; Nitric oxide; Platelet derived growth factor

Indexed keywords

ARGININE; BIOLOGICAL MARKER; DRUG DERIVATIVE; GLYCERYL TRINITRATE; N,N DIMETHYLARGININE; N,N-DIMETHYLARGININE; NITRIC OXIDE;

AGED; ARTICLE; BLOOD; CAROTID ARTERY; CASE CONTROL STUDY; DRUG EFFECT; ECHOGRAPHY; FEMALE; HUMAN; INTIMA; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; SYNDROME X; VASCULAR ENDOTHELIUM; VASODILATATION;

AGED; ARGININE; BIOLOGICAL MARKERS; CAROTID ARTERIES; CASE-CONTROL STUDIES; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MALE; MICROVASCULAR ANGINA; MIDDLE AGED; NITRIC OXIDE; NITROGLYCERIN; TUNICA INTIMA; VASODILATION;

EID: 72449137634     PISSN: 03009734     EISSN: None     Source Type: Journal    
DOI: 10.3109/03009730903225537     Document Type: Article

References (34)

1. Kaski JC. Pathophysiology and management of patients with chest pain and normal coronary arteriograms. Circulation. 2004;109:568-572
2. Egashira K, Inou T, Hirooka Y, Yamada A, Urabe Y, Takeshita A. Evidence of impaired endothelium-dependent coronary vasodilatation in patients with angina pectoris and normal coronary angiograms. N Engl J Med. 1993;328:1659-1664
3. Masci PG, Laclaustra M, Lara JG, Kaski JC. Brachial artery flow-mediated dilatation and myocardial perfusion in patients with cardiac syndrome X. Am J Cardiol. 2005; 95:1478-1480
4. Hurst T, Olson TH, Olson LE, Appleton CP. Cardiac syndrome X and endothelial dysfunction: new concepts in prognosis and treatment. Am J Med. 2006;119:560-566
5. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow mediated vasodilatation of the brachial artery: A report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002;39:257-265
6. Hinderliter AL, Cuaghey M. Assessing endothelial function as a risk factor for cardiovascular disease. Curr Atheroscler Rep. 2003;5:506-513
7. Bisoendial RJ, Hovingh GK, de Groot E, Kastelein JJ, Lansberg PJ, Stroes ES. Measurement of subclinical atherosclerosis: beyond risk factor assessment. Curr Opin Lipidol. 2002;13:595-603.
8. Huang PH, Chen YH, Chen YL, Wu TC, Chen JW, Lin SJ. Vascular endothelial function and circulating endothelial progenitor cells in patients with cardiac syndrome X. Heart. 2007;93:1064-1070
9. Anderson TJ, Uehata A, Gerhard MD, Meredith IT, Knab S, Delagrange D, et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol. 1995;26:1235-1241
10. Bottcher M, Botker HE, Sonne H, Nielsen TT, Czernin J. Endothelium-dependent and -independent perfusion reserve and the effect of L-arginine on myocardial perfusion in patients with syndrome X. Circulation. 1999;99:1795-1801
11. Bellamy MF, Goodfellow J, Tweddel AC, Dunstan FD, Lewis MJ, Henderson AH. Syndrome X and endothelial dysfunction. Cardiovasc Res. 1998;40:410-417
12. Egashira K, Hirooka Y, Kuga T, Mohri M, Takeshita A. Effects of L-arginine supplementation on endothelium- dependent coronary vasodilation in patients with angina pectoris and normal coronary arteriograms. Circulation. 1996;94:130-134
13. Chen JW, Hsu NW, Wu TC, Lin SJ, Chang MS. Longterm angiotensin-converting enzyme inhibition reduces plasma asymmetric dimethylarginine and improves endothelial nitric oxide bioavailability and coronary microvascular function in patients with syndrome X. Am J Cardiol. 2002; 90:974-982
14. Piatti P, Fragasso G, Monti LD, Setola E, Lucotti P, Fermo I, et al. Acute intravenous L-arginine infusion decreases endothelin-1 levels and improves endothelial function in patients with angina pectoris and normal coronary arteriograms: correlation with asymmetric dimethylarginine levels. Circulation. 2003;107:429-436
15. Kolasińska-Kloch W, Leśniak W, Kieć-Wilk B, Malczewska- Malec M. Biochemical parameters of endothelial dysfunction in cardiological syndrome X. Scand J Clin Lab Invest. 2002;62:7-13.
16. Kolasińska-Kloch W, Jabrocka A, Kieć-Wilk B, Leśniak W, Kloch M, Dubiel JS, et al. Relations between endothelial nitric oxide synthase and angiotensin-converting gene polymorphisms and certain biochemical parameters in patients with cardiac syndrome X. Przegl Lek. 2004;61:743-746
17. Kolasilska-Kloch W, Leśniak W, Leszczyń ska-Go?abek I, Kieć-Wilk B, Kloch M. Exercise tolerance and hyperinsulinemia in cardiological syndrome X. Folia Med Cracov. 2004;45:13-23.
18. Sen N, Poyraz F, Tavil Y, Yazici HU, Turfan M, Hizal F, et al. Carotid intima-media thickness in patients with cardiac syndrome X and its association with high circulating levels of asymmetric dimethylarginine. Atherosclerosis. 2009;204: E82-5.
19. Gornik HL, Creager MA. Arginine and endothelial and vascular health. J Nutr. 2004;134:2880S-7S.
20. Okyay K, Cengel A, Sahinarslan A, Tavil Y, Turkoglu S, Biberoglu G, et al. Plasma asymmetric dimethylarginine and L-arginine levels in patients with cardiac syndrome X. Coron Artery Dis. 2007;18:539-544
21. Soysal D, Sumru S, Susam Y. The association of plasma homocysteine, coronary risk factors and serum nitrite in patients with coronary artery disease, vascular syndrome x and healthy subjects. Anadolu Kardiyol Derg. 2003;3:26-34.
22. Piatti PM, Fragasso G, Monti LD, Caumo A, Van Phan C, Valsecchi G, et al. Endothelial and metabolic characteristics of patients with angina and angiographically normal coronary arteries. J Am Coll Cardiol. 1999;34:1452-1460
23. Desideri G, Gaspardone A, Gentile M, Santucci A, Gioffrè PA, Ferri C. Endothelial activation in patients with cardiac syndrome X. Circulation. 2000;102:2359-2364
24. Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev. 1999;79:1283-1316
25. Raines EW. PDGF and cardiovascular disease. Cytokine Growth Factor Rev. 2004;15:237-254
26. Tahara A, Yasuda M, Itagane H, Toda I, Teragaki M, Akioka K, et al. Plasma levels of platelet-derived growth factor in normal subjects and patients with ischemic heart disease. Am Heart J. 1991;122:986-992
27. Nilsson J, Volk-Jovinge S, Svensson J, Landou C, De Faire U, Hamsten A. Association between high levels of growth factors in plasma and progression of coronary atherosclerosis. Intern Med. 1992;232:397-404.
28. Nilsson J, Svensson J, Hamsten A, de Faire U. Increased platelet-derived mitogenic activity in plasma of young patients with coronary atherosclerosis. Atherosclerosis. 1986;61:237-243
29. Billett MA, Adbeish IS, Alrokayan SA, Bennett AJ, Marenah CB, White DA. Increased expression of genes for platelet-derived growth factor in circulating mononuclear cells of hypercholesterolemic patients. Arterioscl Thromb Vasc Biol. 1996;16:399-406.
30. Yeboah J, Sane DC, Crouse JR, Herrington DM, Bowden DW. Low plasma levels of FGF-2 and PDGF-BB are associated with cardiovascular events in type II diabetes mellitus (diabetes heart study). Dis Markers. 2007;23:173-178
31. Harrison AA, Dunbar PR, Neale TJ. Immunoassay of plateletderived growth factor in the blood of patients with diabetes mellitus. Diabetologia. 1994;37:1142-1146
32. Bath PM, Martin JF. Serum platelet-derived growth factor and endothelin concentrations in human hypercholesterolaemia. J Intern Med. 1991;230:313-317
33. Kasprzak JD, Kłosińska M, Drozdz J. Clinical aspects of assessment of endothelial function. Pharmacol Rep. 2006;58:33-40.
34. Ogawa H, Yasue H, Okumura K, Fujii H, Masuda T, Miyao Y, et al. Platelet-derived growth factor is released into the coronary circulation after coronary spasm. Coron Artery Dis. 1993;4:437-442